Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025

Outlook Therapeutics, Inc.

2025-Q3 EPS reported -$1.60 vs consensus -$0.26 ▼ miss (-519.2%)

First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.
Net loss of $20.2M ($0.55 per share), compared to net loss of $0.89 per share in prior-year quarter.
Adjusted net loss of $15.8M ($0.44 per share), excluding $2.3M change in promissory notes and $2.0M warrant liability.
Cash and cash equivalents of $8.9M as of June 30, 2025.
FDA PDUFA goal date for ONS-5010 (bevacizumab-vikg) set for August 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.